LBSP Favicon

Swiss Delegation Explores The Future of Health

Leiden Bio Science Park hosted a Swiss delegation, showcasing innovations in health and life sciences.

Leiden Bio Science Park (LBSP) had the honor of hosting a Swiss delegation, organized by Roche, Novartis, Rijksdienst voor Ondernemend Nederland, Health Holland, and other partners. The visit showcased the innovative collaborations and research driving advancements in health and life sciences.

The program included several highlights:

  • Welcome dinner: Attended by LBSP’s director, Esther Peters, the dinner set the stage for meaningful discussions and connections.
  • Morning session: We joined the delegation to provide insights into LBSP’s contributions to the life sciences sector, kicking off a day of exploration and discovery.

The delegation visited fundamental LBSP locations, including:

  • NecstGen: Demonstrating pioneering work in cell and gene therapy manufacturing.
  • LUMC hiPSC Center: Showcasing research into induced pluripotent stem cells and their diverse applications.
  • Faculty of Science: Dean Jasper Knoester and Esther Peters gave presentations on the vast research opportunities and the activities at Leiden Bio Science Park and the Faculty of Science.

They introduced presentations from:

  • Doser Medical
  • Mimetas
  • Bristol Myers Squibb

These presentations highlighted the diverse health-focused initiatives thriving at LBSP.

The day concluded with a presentation by Thomas Hankemeier on the ExposomeScan, a revolutionary tool connecting environmental factors to medical insights, paving the way for improved health research.

Related posts

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX Secures IND Approval for Phase 3 Trial of VMX-C001 in Emergency Surgery

VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.